Treatment of ANCA-Positive Rapidly Progressive Glomerulonephritis
ANCA-positive rapidly progressive glomerulonephritis (RPGN) is a severe primary kidney disease
for which first-line therapy is guided by relatively strong clinical evidence.
ANCA-negative pauci-immune RPGN is managed identically.
Guidelines for RPGN focus specifically on ANCA-positive disease, which presents frequently
and carries well-established treatment guidance. The same approach applies to
ANCA-negative pauci-immune RPGN.
First-Line Treatment Approach
Initial therapy involves corticosteroids combined with cyclophosphamide.
The specific regimen is selected according to clinical grade, patient age, and dialysis requirement.
An alternative corticosteroid-only approach exists for cases where immunosuppressive agents are not suitable.
The complete regimen — including sequencing, selection criteria, dosing, and full decision algorithm — is available in the structured protocol.
References
DOI: 10.1007/s10157-015-1218-8
- These guidelines focus on ANCA-positive RPGN, which appears frequently and for which there is relatively strong evidence, and on addressing the severe primary diseases, namely lupus nephritis and anti-GBM antibody RPGN.
- For ANCA-negative pauci-immune RPGN, we recommend that the treatment be similar to that of ANCA-positive disease.
- Treatment with corticosteroids and cyclophosphamide has improved the outcome of patients with ANCA-positive RPGN.
- In patients with ANCA-positive RPGN, high or moderate doses of corticosteroids have been shown to improve renal function and survival. However, combination with immunosuppressive agents is more effective; therefore, initial therapy with corticosteroids alone is recommended only in cases in which the use of immunosuppressive agents is not desirable.
View source ↗